Avoro Capital Advisors LLC
Q1 2021 13F-HR Holdings
Net value change ($000)
-16,259
(-0.3%)
New positions
7
Sold out positions
4
Turnover %
16.8%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| VRTX | 300,846 | NEW |
| ASCENDIS PHARMA | 244,872 | NEW |
| XLRN | 208,523 | 105.2% |
| Horizon Therapeutics Public Ltd Co | 170,010 | 25.8% |
| UTHR | 69,208 | 16.0% |
| SNDX | 45,892 | 458.6% |
| APLS | 42,910 | NEW |
| DSGN | 39,702 | NEW |
| MDGL | 30,499 | 22.4% |
| XENE | 22,271 | 51.7% |
Top Reduces (Value $000, Stocks/ETFs)
| ASND | -300,204 | -100.0% |
| Mirati Therapeutics, Inc. | -195,239 | -19.6% |
| SRPT | -138,118 | -46.3% |
| IOVA | -94,720 | -27.2% |
| FOLD | -86,780 | -41.8% |
| Mersana Therapeutics, Inc. | -70,924 | -39.2% |
| PMVP | -52,907 | -40.5% |
| ARENA PHARMACEUTICALS INC | -40,888 | -12.7% |
| ACAD | -39,747 | -38.1% |
| Deciphera Pharmaceuticals, Inc. | -34,149 | -46.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|